Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Turning Point Therapeutics Inc.

https://tptherapeutics.com/

Latest From Turning Point Therapeutics Inc.

Bristol Gets Tumor-Agnostic Second Approval For Augtyro

Already approved for lung cancer, BMS’s ROS1/NTKK inhibitor gets US FDA accelerated approval for solid tumors that are NTRK-fusion positive.

Approvals Business Strategies

Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups

Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.

Financing StartUps and SMEs

Investor Faith In David Hung’s Nuvation Renewed By Anheart Buyout

The acquisition brings two potential best-in-class cancer therapies, which could make Nuvation a commercial company as soon as 2025.

Deals Companies

Finance Watch: FogPharma’s Platform Against Unreachable Targets Attracts $145m Series E

Private Company Edition: FogPharma raised $145m for its clinical-stage drug and earlier programs after bringing on former Johnson & Johnson R&D head Mathai Mammen as CEO last year. Also, BlossomHill closed a $100m series B round and Kenai emerged with $82m in series A cash.

Financing Innovation
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Bristol Myers Squibb Company
    • TP Therapeutics, Inc
UsernamePublicRestriction

Register